MAL application — Competitive Intelligence Brief

MAL application (MAL application) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed MAL protein Small molecule

Target snapshot

MAL application (MAL application) — Dong-A University. MAL application works by modulating the activity of the MAL protein.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MAL application TARGET	MAL application	Dong-A University	marketed		MAL protein
Cleocin	clindamycin	Generic (originally Upjohn/Pfizer)	marketed	Lincosamide antibiotic	50S ribosomal protein L10	1970-01-01
Minocyclin	Minocyclin	University of Southern California	marketed		30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B
Roxacin	ROXITHROMYCIN		marketed	roxithromycin	Motilin receptor, 50S ribosomal protein L10, Alpha-1B adrenergic receptor
BPaL(M) regimen	BPaL(M) regimen	Asan Medical Center	marketed	Anti-tuberculosis combination regimen	Multiple: ATP synthase (bedaquiline), cell wall synthesis (pretomanid), ribosomal protein synthesis (linezolid), DNA gyrase (moxifloxacin)
SPECT	SPECT	Tomsk National Research Medical Center of the Russian Academy of Sciences	marketed		30S ribosomal protein S12
nitrofurantoin monohydrate/macrocrystalline capsules	nitrofurantoin monohydrate/macrocrystalline capsules	University of California, San Diego	marketed	Nitrofuran antibiotic	Bacterial DNA and ribosomal proteins (non-specific after activation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.